Mergers & Acquisitions ·
Ping An Biomedical to acquire three tumor cell patents for up to $2.5M in planned deal
PASWPing An Biomedical Co., Ltd.
Ping An Biomedical Co., Ltd. entered into a non-binding letter of intent with Future Biotechnology Group Co., Limited on October 22, 2026, to acquire three tumor cell-related medical technology patents covering oncology diagnosis and treatment, cell detection, bioengineering, and biomarker technologies for consideration ranging from US $2 million to US $2.5 million. The transaction is subject to due diligence and the execution of a definitive agreement. Management intends to incorporate these assets into its healthcare technology IP reserve to support long-term biomedical R&D strategies, though it does not expect near-term material revenue generation. Ping An Biomedical Co., Ltd. operates as an apparel supply chain management service provider while expanding into healthcare and biomedical technologies.